肾肝宁胶囊联合他克莫司治疗肾病综合征的临床研究

Clinical study on Shenganning Capsules combined with tacrolimus in treatment of nephrotic syndrome

目的研究肾肝宁胶囊联合他克莫司胶囊治疗肾病综合征的临床疗效。方法选取2016年4月-2019年4月天津市第三中心医院收治的100例肾病综合征患者为研究对象,所有患者随机分为对照组和治疗组,两组各50例。对照组口服他克莫司胶囊,0.05 mg/(kg·d),使血药浓度维持在10 ng/mL;治疗组在对照组基础上口服肾肝宁胶囊,3粒/次,3次/d。两组患者持续治疗2个月。观察两组的临床疗效,比较两组的肾功能指标、血清炎性因子水平。结果治疗后,对照组和治疗组的总有效率分别为82.00%、94.00%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者24 h尿蛋白、血尿素氮和血肌酐水平均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组患者24h尿蛋白、血尿素氮和血肌酐水平明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者肿瘤坏死因子-α(TNF-α)、C-反应蛋白(CRP)水平均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组患者TNF-α、CRP水平均明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论肾肝宁胶囊联合他克莫司胶囊治疗肾病综合征具有较好的治疗效果,可改善肾功能指标,降低炎性反应,具有一定的临床推广应用价值。

Objective To study the efficacy of Shenganning Capsules combined with Tacrolimus Capsules in treatment of nephrotic syndrome. Methods Patients(100 cases) with nephrotic syndrome in Tianjin Third Central Hospital from April 2016 to April 2019 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Tacrolimus Capsules, 0.05 mg/(kg·d), maintained the blood concentration at 10 ng/mL. Patients in the treatment group were po administered with Shenganning Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacies were evaluated, and renal function indexes and serum levels of inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.00% and 94.00%, respectively, and there was difference between two groups(P < 0.05). After treatment, the levels of 24 h urine protein, blood urea nitrogen, and blood creatinine in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the renal function indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of TNF-α and CRP in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group(P < 0.05). Conclusion Shenganning Capsules combined with Tacrolimus Capsules has clinical curative effect in treatment of nephrotic syndrome, can improve renal function index, and reduce inflammatory response, which has a certain clinical application value.